Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,184,100
  • Shares Outstanding, K 42,449
  • Annual Sales, $ 182,950 K
  • Annual Income, $ -115,550 K
  • EBIT $ -87 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.57
  • Price/Sales 6.54
  • Price/Cash Flow N/A
  • Price/Book 8.82

Options Overview Details

View History
  • Implied Volatility 52.27% (-3.28%)
  • Historical Volatility 47.15%
  • IV Percentile 30%
  • IV Rank 34.34%
  • IV High 79.61% on 04/08/25
  • IV Low 37.97% on 08/20/25
  • Expected Move (DTE 23) 7.57 (10.04%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 22
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 1.32
  • Today's Open Interest 6,597
  • Open Int (30-Day) 4,457
  • Expected Range 67.85 to 82.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.05
  • Number of Estimates 1
  • High Estimate 0.05
  • Low Estimate 0.05
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +107.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.54 +24.14%
on 02/13/26
80.00 -6.06%
on 02/24/26
+6.79 (+9.94%)
since 01/23/26
3-Month
60.54 +24.14%
on 02/13/26
85.25 -11.84%
on 12/09/25
-3.72 (-4.72%)
since 11/25/25
52-Week
38.51 +95.16%
on 08/01/25
85.25 -11.84%
on 12/09/25
+33.86 (+82.02%)
since 02/25/25

Most Recent Stories

More News
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million , an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion...

TARS : 74.30 (-0.95%)
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical...

TARS : 74.30 (-0.95%)
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23,...

TARS : 74.30 (-0.95%)
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5 th Annual Ophthalmology...

TARS : 74.30 (-0.95%)
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual Healthcare...

TARS : 74.30 (-0.95%)
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly  XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter...

TARS : 74.30 (-0.95%)
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4,...

TARS : 74.30 (-0.95%)
Bank of America Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $85.00. The company’s shares closed yesterday at $69.75.Elevate...

TARS : 74.30 (-0.95%)
Bank of America Securities Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $80.00. The company’s shares closed yesterday at $58.77.Elevate...

TARS : 74.30 (-0.95%)
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 74.30 (-0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 84.90
2nd Resistance Point 82.45
1st Resistance Point 78.73
Last Price 74.30
1st Support Level 72.56
2nd Support Level 70.11
3rd Support Level 66.39

See More

52-Week High 85.25
Last Price 74.30
Fibonacci 61.8% 67.40
Fibonacci 50% 61.88
Fibonacci 38.2% 56.36
52-Week Low 38.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar